Pharmaceutical

STAT+: Pharmalittle: Data confirm benefits and risks of...

The benefits and risks of an Eli Lilly treatment for Alzheimer's were confirmed ...

ARCH Venture Partners rises to the top of STAT’s 2023 b...

Long-running firm ARCH Venture Partners has topped STAT's annual ranking of biot...

STAT+: Flagship, Pfizer team up in deal worth up to $7 ...

The new Pfizer partnership with Flagship will fund the development of up to 10 d...

STAT+: Startup Neumora takes a novel depression drug to...

Neumora, a privately held biotech company, is moving into the final phase of tes...

STAT+: As digital health tech proliferates, a new insti...

“Increasingly, I think patients, health insurers, providers and even investors a...

From rapid cooling body bags to ‘prescriptions’ for AC,...

From body bags for rapid cooling to "prescriptions" for air conditioners, doctor...

STAT+: Conservative group opposing PBM reform spends re...

A conservative group opposing reforming pharmacy middlemen and targeting GOP sen...

STAT+: Medicare has a new plan to address drug shortage...

Medicare has a new proposal to pay hospitals more to stockpile essential drugs, ...

Opinion: AI can’t replicate this key part of practicing...

Any assertion that AI will replace health care providers or make our roles less ...

Hearing aids may slow mental decline in those at higher...

New research ties hearing aids to slower cognitive decline in those at higher ri...

Global childhood vaccinations edge closer to pre-pandem...

HPV vaccination rates surpassed pre-pandemic levels to reach 21% of girls global...

STAT+: Medicare to cover more brain scans for Alzheimer...

Medicare proposed covering more brain scans for Alzheimer’s patients, which will...

STAT+: Key House panel plots a new health care package ...

Leaders of the House Ways & Means Committee are planning to release their own he...

Antengene’s multiple myeloma therapy receives approval ...

Antengene has received approval in Hong Kong for a new drug application (NDA) fo...

Vivoryon issues updates on its Alzheimer’s therapy prog...

The complete data readouts of two-Phase II trials are expected in 2024, with an ...

Korro Bio enters merger deal with Frequency Therapeutics

Korro Bio has signed a definitive merger agreement with Frequency Therapeutics t...